21 completed, 5 terminated, 2 unknown, 1 withdrawn. 17 Phase 1, 14 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 12, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 14 | Completed 9, Terminated 4, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Merrimack Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma Nanoliposomal Irinotecan, Temozolomide - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Terminated | Brown University | 12 | 2017-11-30 | 2022-12-13 |
| A Study Evaluating MM-310 in Patients With Solid Tumors MM-310 - Solid Tumors, Urothelial Carcinoma | Phase 1 | Unknown | Merrimack Pharmaceuticals | 34 | 2017-02-22 | 2018-02-27 |
| Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer MM-151, nal-IRI, Leucovorin - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | Merrimack Pharmaceuticals | 2016-07-01 | 2017-01-11 | |
| A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer MM-398, Irinotecan, Leucovorin (LV) - Unresectable Advanced Cancer | Phase 1 | Completed | GERCOR - Multidisciplinary Oncology Cooperative Group | 10 | 2015-11-18 | 2017-01-31 |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib MM-151, MM-121, MM-141 - Colorectal Cancer, Non-small Cell Lung Cancer | Phase 1 | Terminated | Merrimack Pharmaceuticals | 5 | 2015-08-01 | 2017-09-05 |
| A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer MM-141, Placebo, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Merrimack Pharmaceuticals | 88 | 2015-05-01 | 2018-09-18 |
| A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC MM-121, Docetaxel - Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Terminated | Elevation Oncology | 153 | 2015-02-01 | 2021-10-12 |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients MM-302, Gemcitabine, Capecitabine - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 / Phase 3 | Terminated | Merrimack Pharmaceuticals | 113 | 2014-07-01 | 2017-01-06 |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach MM-111, Paclitaxel, Trastuzumab - HER-2 Gene Amplification, Esophagus Cancer | Phase 2 | Terminated | Merrimack Pharmaceuticals | 84 | 2013-01-01 | 2017-06-22 |
| A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors MM-141 - Hepatocellular Carcinoma | Phase 1 | Completed | Merrimack Pharmaceuticals | 42 | 2012-11-01 | 2016-08-04 |
| Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment MM-151, MM-151 + irinotecan - Advanced Solid Tumors, Colorectal Cancer | Phase 1 | Completed | Merrimack Pharmaceuticals | 112 | 2012-01-01 | 2018-03-21 |
| Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer MM-398, 5 Fluorouracil, Leucovorin - Metastatic Pancreatic Cancer | Phase 3 | Completed | Merrimack Pharmaceuticals | 417 | 2011-11-01 | 2016-06-17 |
| A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers MM-121 (SAR256212), SAR245408 - Solid Tumor Cancers | Phase 1 | Completed | Sanofi | 26 | 2011-11-01 | 2014-06-13 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers MM-121, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Merrimack Pharmaceuticals | 223 | 2011-10-01 | 2016-05-12 |
| A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers MM-121, Irinotecan, Cetuximab - Colorectal Cancer, Squamous Cell Head and Neck Cancer | Phase 1 | Completed | Merrimack Pharmaceuticals | 48 | 2011-10-01 | 2016-09-08 |
| Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors MM-121, Carboplatin, Pemetrexed - Solid Tumors | Phase 1 | Completed | Merrimack Pharmaceuticals | 43 | 2011-10-01 | 2016-09-14 |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer MM-121, Paclitaxel - ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients | Phase 2 | Completed | Merrimack Pharmaceuticals | 196 | 2011-08-01 | 2016-05-03 |
| Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with trastuzumab q3w - Breast Cancer | Phase 1 | Unknown | Merrimack Pharmaceuticals | 75 | 2011-03-01 | 2017-01-06 |
| A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111 - HER-2 Gene Amplification | Phase 1 | Completed | Merrimack Pharmaceuticals | 100 | 2011-01-01 | 2015-12-16 |
| A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers MM-121, Paclitaxel - Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer | Phase 1 | Completed | Merrimack Pharmaceuticals | 41 | 2010-10-01 | 2016-09-08 |
Showing 20 of 29. Sign in to see all of them.
Neoplasms (8) · Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Arthritis, Rheumatoid (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Fibromatosis, Gingival, 2 (2) · Head and Neck Neoplasms (2) · Lethal Congenital Contracture Syndrome 2 (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2)
seribantumab (11) · Paclitaxel (5) · Trastuzumab (5) · MM-111 (4) · irinotecan sucrosofate (4) · Fluorouracil (3) · Gemcitabine (3) · Irinotecan (3) · Istiratumab (3) · Leucovorin (3) · MM-151 (3) · Capecitabine (2) · Docetaxel (2) · gancotamab (2) · 130-nm albumin-bound paclitaxel (1)
United States (27) · Canada (6) · France (6) · Germany (6) · Spain (6) · Czechia (2) · Hungary (2) · Italy (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1)
Victor Moyo, MD (6) · Akos Czibere, MD, PhD (2) · Alan Mentor, MD (1) · Benoist Chibaudel, MD (1) · Chrystal Louis, MD, MPH (1) · Crystal Denlinger, MD (1) · Dr. Stephen Foster (1) · Eliel Bayever, MD (1) · Gerald Krueger (1) · Howard Safran, MD (1) · Keedy L Vicki, MD (1) · Kwok Kin Wong, MD (1)
PMID 26615328, PMID 27259714, PMID 27998236, PMID 28298546, PMID 30414528, PMID 30654298, PMID 30842038, PMID 30975923, PMID 31400383, PMID 31789476, PMID 31856081, PMID 31912800, PMID 33214082, PMID 33284237, PMID 34250553